April 26, 2024
A marketing authorization should be given for the medicinal product Obgemsa (vibegron) for treating adults with overactive bladder (OAB) syndrome, the European Medicines Agency (EMA) has […]
April 26, 2024
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) this week recommended new contraindications on the coadministration of the protease […]
April 26, 2024
At an April 25 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for two biosimilar medicines: Tofidence, […]
April 26, 2024
At its April 2024 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) made recommendations for Fruzaqla, Truqap, and Eribulin Baxter […]
April 26, 2024
Share on PinterestA new study suggests regular stair climbing can lower the risk of heart disease and death from all causes. Igor Alecsander/Getty Images New research […]
April 26, 2024
First Nations patients in Alberta have higher rates of incomplete emergency department (ED) care than do non–First Nations patients, often leaving early because of concerns about […]
April 26, 2024
An intervention aiming to improve spirituality significantly improved endothelial function and lowered systolic blood pressure, preliminary results of a new study suggested. The intervention consisted of […]
April 26, 2024
The US Food and Drug Administration (FDA) has approved the gene therapy fidanacogene elaparvovec (Beqvez) for adults with hemophilia B, a rare bleeding disorder that affects […]
April 26, 2024
Image By: Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research and Hilary Marston, M.D., M.P.H., Chief Medical Officer The Biologics Price Competition and Innovation […]